Aveo Pharmaceuticals Inc (AVEO) Return on Investment ROI from the third quarter of 2022 to third quarter of 2021 and for the year 2022, average high and low, overall ranking from Sep 30 2022 to Sep 30 2021 - CSIMarket
CSIMarket
 


Aveo Pharmaceuticals Inc   (AVEO)


Aveo Pharmaceuticals Inc's ROI from its third quarter of 2022 to the third quarter of 2021 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Aveo Pharmaceuticals Inc's ROI in the third quarter of 2022?
Aveo Pharmaceuticals Inc recorded a cumulative net loss of $-29 million during 12 months ending in the third quarter of 2022, resulting in a negative return on investment (ROI) of -40.06%.

Within the Healthcare sector 577 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2022 from 0 to 4510.

Definition and Formula of Return on Investment



Return On Investment (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Investment Change TTM -14.32 % 3.66 % 31.76 % 121.72 % 129.51 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 59 67 78 87 87
Return On Investment (TTM) -40.06 % -45.49 % -47.8 % -56.75 % -68.07 %
AVEO's Overall Ranking # 4510 # 0 # 0 # 0 # 0
Seq. Investment Change TTM -8.77 % -8.29 % -7.82 % 11.1 % 10.37 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -29 -36 -41 -53 -58




Return On Investment AVEO's Ranking
Within: No.
Industry # 228
Sector # 578
Overall # 4510

Return On Investment Statistics
High Average Low
180.27 %
-85.99 %
-321.99 %
(Sep 30 2019)   (Sep 30 2017)







Financial Statements
Aveo Pharmaceuticals Inc's III. Quarter Investments $ 59 Millions AVEO's Balance sheet
Aveo Pharmaceuticals Inc's III. Quarter Income $ -3 Millions Quarterly AVEO's Income Statement
AVEO's Income by Division See AVEO's Income by Division


AVEO Annual Return On Investment (Dec 31 2021)
2021
(Dec 31 2020)
2020
(Dec 31 2019)
2019
(Dec 31 2018)
2018
(Dec 31 2017)
2017
Total Investments in Millions 87 49 27 10 18
Y / Y Investment Growth 76.56 % 82.15 % 174.29 % -45 % 5.41 %
Net Income in Millions -53 -36 9 -5 -65
Y / Y Net Income Growth - - - - -
Annual Return On Investment -61.59 % -72.54 % 34.86 % -54.28 % -364.24 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AVEO's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AVEO's Competitors
Subscribers only: Roi for Aveo Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for AVEO's Customers

Other Ratios
AVEO's Roa AVEO's Inventory Turnover Ratio AVEO's Growth Rates AVEO's Dividend Statistics
AVEO's Profitability Ratios AVEO's Asset Turnover Ratio AVEO's Dividend Growth
AVEO's Roe AVEO's Valuation Ratios AVEO's Financial Strength Ratios AVEO's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2022, within Healthcare Sector ROI


Date modified: 2026-09-08T15:10:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.